A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Painful Diabetes Neuropathy, Followed by a Double-Blind Safety Extension and an Open-Label Safety Extension.

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Painful Diabetes Neuropathy, Followed by a Double-Blind Safety Extension and an Open-Label Safety Extension.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Jul 2014

At a glance

  • Drugs Fulranumab (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 23 Mar 2013 Tolerability (peripheral nerve function) results presented at the 65th Annual Meeting of the American Academy of Neurology.
    • 23 Mar 2013 Results presented at the 65th Annual Meeting of the American Academy of Neurology.
    • 31 Aug 2012 Primary endpoint 'Pain-intensity' has been met according to results presented at the 14th World Congress on Pain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top